Market Overview:
The global intravenous iron drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of anemia, rising geriatric population, and growing demand for parenteral nutrition products. Based on type, the global intravenous iron drugs market is segmented into ferric gluconate, ferric carboxymaltose, iron sucrose, and iron dextran. Ferric gluconate held the largest share of the market in 2017 owing to its high efficacy and safety profile. However, ferric carboxymaltose is expected to grow at a higher CAGR during the forecast period as it offers several benefits over other types of intravenous iron drugs such as shorter infusion time and fewer side effects. Based on application, the global intravenous iron drugs market is segmented into nephrology, gynecology & obstetrics,, gastroenterology,, oncology,, cardiology,, and others (including hematology/oncology). Nephrology held the largest share of this market in 2017 due to increasing incidence rates of renal failure across all regions worldwide. However,.
Product Definition:
Intravenous iron drugs are used to treat iron deficiency anemia. Iron is essential for the production of hemoglobin, which carries oxygen throughout the body. Intravenous iron drugs are given as an infusion into a vein, and they work quickly to raise blood levels of iron.
Ferric Gluconate:
Ferric gluconate is a salt that contains iron, which is used as an additive in intravenous (IV) drugs to enhance the absorption of iron from the blood. It works by enhancing the ability of cells to absorb iron from hemoglobin. The product has no effect on non-sideric organs such as liver and kidneys.
The global ferric gluconate market size was valued at USD 41 million in 2016.
Ferric Carboxymaltose:
Ferric carboxymaltose is a form of iron chelating agent. It has been used in intravenous (IV) drugs to increase the amount of available iron and improve its absorption by the body. The drug was first approved by the U.S Food and Drug Administration (FDA) in February 2000 as an injection for intractable angina pectoris, which is a type of heart disease that causes frequent attacks of chest pain.
Application Insights:
The others segment includes infectious diseases, nephrology, and other applications. The others segment held the largest share of the global intravenous iron drugs market in 2017 due to a large number of patients suffering from chronic diseases such as cancer and diabetes. These chronic diseases require long-term treatment and involve several medical procedures such as dialysis or kidney transplantation for curing them. Thus, there is a growing demand for effective medications that cure these conditions without any side effects. Intravenous iron drugs are one of the best solutions to treat various types of infections including tuberculosis because they have no known side effects; however, their usage in treating these infections is limited to clinical trials only at this time since they can cause harm if not used correctly (Iron Sucrose).
Regional Analysis:
In 2017, North America dominated the global intravenous iron drugs market with a revenue share of around 40.0%. The growth is majorly attributed to the presence of high healthcare expenditure and favorable reimbursement policies in this region. In addition, increasing prevalence of kidney and liver diseases drives the demand for intravenous iron drugs in this region. For instance, as per statistics published by Liver International (2017), chronic hepatitis B virus infection rate has increased by 25% from 2014 to 2016 in U.S.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income coupled with improving healthcare infrastructure especially in developing countries such as India and China.
Growth Factors:
- Increasing prevalence of anemia: The increasing prevalence of anemia is one of the key growth drivers for the intravenous iron drugs market. According to a study by the World Health Organization (WHO), approximately 1.62 billion people were affected by anemia in 2013, and this number is expected to increase to 1.85 billion by 2025. This growing population base is likely to drive demand for intravenous iron drugs in the coming years.
- Rising geriatric population: The global geriatric population is growing at a rapid pace and this is expected to create significant demand for intravenous iron drugs in the near future. According to estimates, the geriatric population (aged 65 years or above) accounted for 12% of the world’s population in 2010, and this number is projected to reach nearly 20% by 2050. This rising geriatric population will create significant opportunities for players operating in the intravenous iron drugs market over the forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Intravenous Iron Drugs Market Research Report
By Type
Ferric Gluconate, Ferric Carboxymaltose, Iron Sucrose, Iron Dextran
By Application
Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others
By Companies
Allergan, AMAG Pharmaceuticals, Daiichi Sankyo, Galenica, Pharmacosmos, Nippon Shinyaku, NOXXON Pharma, Rockwell Medical, Sanofi, Wanbang Biopharmaceutical, Allergan
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Intravenous Iron Drugs Market Report Segments:
The global Intravenous Iron Drugs market is segmented on the basis of:
Types
Ferric Gluconate, Ferric Carboxymaltose, Iron Sucrose, Iron Dextran
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan
- AMAG Pharmaceuticals
- Daiichi Sankyo
- Galenica
- Pharmacosmos
- Nippon Shinyaku
- NOXXON Pharma
- Rockwell Medical
- Sanofi
- Wanbang Biopharmaceutical
- Allergan
Highlights of The Intravenous Iron Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Ferric Gluconate
- Ferric Carboxymaltose
- Iron Sucrose
- Iron Dextran
- By Application:
- Nephrology
- Gynecology & Obstetrics
- Gastroenterology
- Oncology
- Cardiology
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Intravenous Iron Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Intravenous iron drugs are medications that are given through a vein (intravenously). These drugs help to improve the blood flow and oxygen levels in the body.
Some of the key players operating in the intravenous iron drugs market are Allergan, AMAG Pharmaceuticals, Daiichi Sankyo, Galenica, Pharmacosmos, Nippon Shinyaku, NOXXON Pharma, Rockwell Medical, Sanofi, Wanbang Biopharmaceutical, Allergan.
The intravenous iron drugs market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Intravenous Iron Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Intravenous Iron Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Intravenous Iron Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Intravenous Iron Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Intravenous Iron Drugs Market Size & Forecast, 2018-2028
4.5.1 Intravenous Iron Drugs Market Size and Y-o-Y Growth
4.5.2 Intravenous Iron Drugs Market Absolute $ Opportunity
Chapter 5 Global Intravenous Iron Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Intravenous Iron Drugs Market Size Forecast by Type
5.2.1 Ferric Gluconate
5.2.2 Ferric Carboxymaltose
5.2.3 Iron Sucrose
5.2.4 Iron Dextran
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Intravenous Iron Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Intravenous Iron Drugs Market Size Forecast by Applications
6.2.1 Nephrology
6.2.2 Gynecology & Obstetrics
6.2.3 Gastroenterology
6.2.4 Oncology
6.2.5 Cardiology
6.2.6 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Intravenous Iron Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Intravenous Iron Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Intravenous Iron Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Intravenous Iron Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Intravenous Iron Drugs Market Size Forecast by Type
9.6.1 Ferric Gluconate
9.6.2 Ferric Carboxymaltose
9.6.3 Iron Sucrose
9.6.4 Iron Dextran
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Intravenous Iron Drugs Market Size Forecast by Applications
9.10.1 Nephrology
9.10.2 Gynecology & Obstetrics
9.10.3 Gastroenterology
9.10.4 Oncology
9.10.5 Cardiology
9.10.6 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Intravenous Iron Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Intravenous Iron Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Intravenous Iron Drugs Market Size Forecast by Type
10.6.1 Ferric Gluconate
10.6.2 Ferric Carboxymaltose
10.6.3 Iron Sucrose
10.6.4 Iron Dextran
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Intravenous Iron Drugs Market Size Forecast by Applications
10.10.1 Nephrology
10.10.2 Gynecology & Obstetrics
10.10.3 Gastroenterology
10.10.4 Oncology
10.10.5 Cardiology
10.10.6 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Intravenous Iron Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Intravenous Iron Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Intravenous Iron Drugs Market Size Forecast by Type
11.6.1 Ferric Gluconate
11.6.2 Ferric Carboxymaltose
11.6.3 Iron Sucrose
11.6.4 Iron Dextran
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Intravenous Iron Drugs Market Size Forecast by Applications
11.10.1 Nephrology
11.10.2 Gynecology & Obstetrics
11.10.3 Gastroenterology
11.10.4 Oncology
11.10.5 Cardiology
11.10.6 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Intravenous Iron Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Intravenous Iron Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Intravenous Iron Drugs Market Size Forecast by Type
12.6.1 Ferric Gluconate
12.6.2 Ferric Carboxymaltose
12.6.3 Iron Sucrose
12.6.4 Iron Dextran
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Intravenous Iron Drugs Market Size Forecast by Applications
12.10.1 Nephrology
12.10.2 Gynecology & Obstetrics
12.10.3 Gastroenterology
12.10.4 Oncology
12.10.5 Cardiology
12.10.6 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Intravenous Iron Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Intravenous Iron Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Intravenous Iron Drugs Market Size Forecast by Type
13.6.1 Ferric Gluconate
13.6.2 Ferric Carboxymaltose
13.6.3 Iron Sucrose
13.6.4 Iron Dextran
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Intravenous Iron Drugs Market Size Forecast by Applications
13.10.1 Nephrology
13.10.2 Gynecology & Obstetrics
13.10.3 Gastroenterology
13.10.4 Oncology
13.10.5 Cardiology
13.10.6 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Intravenous Iron Drugs Market: Competitive Dashboard
14.2 Global Intravenous Iron Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Allergan
14.3.2 AMAG Pharmaceuticals
14.3.3 Daiichi Sankyo
14.3.4 Galenica
14.3.5 Pharmacosmos
14.3.6 Nippon Shinyaku
14.3.7 NOXXON Pharma
14.3.8 Rockwell Medical
14.3.9 Sanofi
14.3.10 Wanbang Biopharmaceutical
14.3.11 Allergan
